当前位置:首页 - 行情中心 - 上海医药(601607) - 财务分析

上海医药

(601607)

  

流通市值:393.27亿  总市值:753.12亿
流通股本:19.36亿   总股本:37.08亿

上海医药(601607)财务分析

净利润 + 每股收益
------
  • 净利润(亿元)
  • 每股收益(元)

    截至第三季度实现净利润50.23亿元,每股收益1.09元。

股东权益 + 未分配利润
------
  • 股东权益(亿元)
  • 未分配利润(亿元)

    截至第三季度最新股东权益8315751.19万元,未分配利润3606145.63万元。

总资产 + 负债
------
  • 总资产(亿元)
  • 负债(亿元)

    截至第三季度最新总资产22374134.58万元,负债14058383.39万元。

利润表
报告期2024-09-302024-06-302024-03-312023-12-31
营业总收入209,628,733,748.35139,413,145,524.4370,152,787,484.98260,295,088,943.53
营业总成本203,433,368,171.18134,890,168,760.0167,891,869,133.58253,008,863,712.03
营业利润6,668,766,941.124,830,896,881.372,414,682,250.747,667,234,704.32
利润总额6,644,377,262.894,822,020,675.992,416,700,316.257,054,296,738.48
净利润5,023,298,063.883,597,363,036.621,865,572,336.295,166,570,284.26
其他综合收益-26,585,406.09-35,643,937.69463,240.42-126,719,890.54
综合收益总额4,996,712,657.793,561,719,098.931,866,035,576.715,039,850,393.72
资产负债表
报告期2024-09-302024-06-302024-03-312023-12-31
流动资产合计173,787,729,817.04171,602,970,409.07167,405,500,979.62162,433,862,348.46
非流动资产合计49,953,615,974.6649,732,901,419.9950,011,455,764.849,538,671,418.34
资产总计223,741,345,791.7221,335,871,829.06217,416,956,744.42211,972,533,766.8
流动负债合计129,532,122,995.82129,104,115,224.21125,273,429,065.57122,371,879,034.89
非流动负债合计11,051,710,878.2510,003,135,409.7910,057,880,361.259,274,561,766.98
负债合计140,583,833,874.07139,107,250,634135,331,309,426.82131,646,440,801.87
归属于母公司股东权益合计70,865,778,972.8369,990,684,153.2970,061,915,248.1268,524,143,051.35
股东权益合计83,157,511,917.6382,228,621,195.0682,085,647,317.680,326,092,964.93
负债和股东权益合计223,741,345,791.7221,335,871,829.06217,416,956,744.42211,972,533,766.8
现金流量表
报告期2024-09-302024-06-302024-03-312023-12-31
经营活动现金流入小计219,416,492,667.27144,842,680,880.6167,811,733,741.17286,783,410,440.97
经营活动现金流出小计216,633,528,211.01144,327,377,497.5873,285,333,453.81281,551,890,713.87
经营活动产生的现金流量净额2,782,964,456.26515,303,383.03-5,473,599,712.645,231,519,727.1
投资活动现金流入小计19,354,120,323.7312,895,694,795.510,531,742,135.8129,309,350,002.95
投资活动现金流出小计18,996,138,579.9410,862,517,080.298,690,009,617.1431,801,222,841.47
投资活动产生的现金流量净额357,981,743.792,033,177,715.211,841,732,518.67-2,491,872,838.52
筹资活动现金流入小计55,183,838,786.6341,732,726,990.6321,521,264,917.5779,711,765,730.44
筹资活动现金流出小计55,047,062,826.0637,969,626,925.6418,271,012,368.9779,479,914,839.71
筹资活动产生的现金流量净额136,775,960.573,763,100,064.993,250,252,548.6231,850,890.73
汇率变动对现金及现金等价物的影响-22,872,683.73-8,187,361.977,736,229.48-5,580,083.93
现金及现金等价物净增加额3,254,849,476.896,303,393,801.26-373,878,415.892,965,917,695.38
期末现金及现金等价物余额30,754,658,478.0933,803,202,802.4627,125,930,585.3127,499,809,001.2
最新报告期:2025-01-22
研究机构分析师预测每股收益(元)更新日
2024年2025年2026年
浙商证券孙建,王帅1.351.531.712025-01-22
中金公司朱言音1.261.381.452025-01-06
中信证券宋硕,陈竹1.411.571.762025-01-02
国金证券赵海春1.361.651.972025-01-01
中信证券宋硕,陈竹1.411.571.762024-12-05
TOP↑